MCA
GSK icon

Maryland Capital Advisors’s GSK GSK Stock Holding History

Maryland Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-320
Closed -$17K – 245
2022
Q2 		$17K Sell
320
-71
-18% -$3.92K 0.02% 144
2022
Q1 		$21K Hold
391
– – 0.02% 130
2021
Q4 		$22K Buy
+391
New +$20.3K 0.02% 124

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Maryland Capital Advisors's GSK Position: Q3 2022 in Review

Maryland Capital Advisors sold out of GSK (GSK) in Q3 2022, closing a stake of 320 shares — an estimated $17K sold.

Maryland Capital Advisors first reported a position in GSK in Q4 2021 and held it in 3 quarters. The position peaked at $22K in Q4 2021. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

  • Maryland Capital Advisors reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
  • Maryland Capital Advisors sold 320 GSK shares in Q3 2022, an estimated $17K.
  • Maryland Capital Advisors first reported a position in GSK in Q4 2021 and held it in 3 quarters.
  • Maryland Capital Advisors's GSK position peaked at $22K in Q4 2021.
  • 742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Maryland Capital Advisors's 13F filing for Q3 2022, filed 3 Nov 2022.